Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics
Codexis, Inc. (CDXS)
Last codexis, inc. earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.codexis.com/investors
Company Research
Source: GlobeNewswire
—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will demonstrate real-world application of its enzymatic synthesis platform via three presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany. Codexis management will hold an investor conference call at 4:30 pm Eastern Time on November 14, 2024, to review and discuss the data presented. In a joint poster with Bachem, one of the world’s leading CDMOs in siRNA manufacturing, Codexis will feature data demonstrating the superiority of its d
Show less
Read more
Impact Snapshot
Event Time:
CDXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXS alerts
High impacting Codexis, Inc. news events
Weekly update
A roundup of the hottest topics
CDXS
News
- Codexis, Inc. (NASDAQ: CDXS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $11.00 price target on the stock.MarketBeat
- Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics [Yahoo! Finance]Yahoo! Finance
- Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi TherapeuticsGlobeNewswire
- Codexis Announces Appointment of Raymond De Vré, PhD, to Board of DirectorsGlobeNewswire
- Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics [Yahoo! Finance]Yahoo! Finance
CDXS
Earnings
- 10/31/24 - Miss
CDXS
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/12/24 - Form 4
- 11/12/24 - Form 3
- CDXS's page on the SEC website